ClinicalTrials.gg
Not yet recruitingNCT07942298URGEUpdated Nov 17, 2026

Utility of Respiratory Biomarker Guidance in Exacerbations

An interventional study of Respiratory pathogen detection via molecular PCR and C-reactive protein (CRP) quantification in Asthma Acute and COPD Acute Exacerbation, sponsored by Université de Sherbrooke. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Health services research

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 429 studies in Asthma with a site in Canada — 42 open to participants now, 57 under way, 11 of them phase 3. Asthma · Canada.

Planned enrollment
154th of 367
200 · median 110
Started
2027
the only one that year
No phase
85 of 429
14 open now
Primary completion
2028-12
later than 47 of 56 live
Registered
429th of 429
by date

Among the 429 studies in Asthma with a site in Canada, this one is the 154th largest by planned enrollment of the 367 interventional ones that give a count, is the only one that started in 2027, is one of 85 with no phase, reaches primary completion later than 47 of the 56 other live ones, and was the 429th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

42 of the 429 studies in Asthma with a site in Canada are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Asthma with a site in Canada, or all of them as a file.
02

Study summary

People with asthma or chronic obstructive pulmonary disease (COPD) often come to the emergency department because their breathing suddenly gets worse. These flare-ups are called exacerbations. Many of these episodes are caused by viruses or inflammation, not bacteria. However, clinicians still frequently prescribe antibiotics, even when they are unlikely to help. Unnecessary antibiotic use can cause side effects, increase healthcare costs, and contribute to antibiotic resistance, which is a growing public health problem.

The URGE study aims to find a better way to decide when antibiotics are truly needed during asthma or COPD attacks in the emergency department. The study will test whether using two rapid bedside tests can safely reduce unnecessary antibiotic prescriptions.

The first test is a rapid molecular test that looks for common respiratory viruses and certain bacteria using a nasopharyngeal swab. Results are available within about 15 to 20 minutes. The second test measures C-reactive protein (CRP) from a small blood sample. CRP is an inflammation marker that tends to be higher when a bacterial infection is present. Together, these tests give doctors quick information about whether an infection is likely viral, bacterial, or non-infectious.

URGE will recruit 200 adults who come to the emergency department with an asthma or COPD exacerbation to take part in the study. After providing consent, participants will be randomly assigned to one of two groups. In both groups, participants will complete both rapid tests. In one group, the test results will be shared with the treating doctor right away and can be used to help guide treatment decisions. In the other group, the doctor will not see the test results, and care will follow usual practice. Doctors will always be free to make their own clinical decisions, regardless of test results.

The main outcome the study will measure is whether or not patients are prescribed antibiotics when they leave the emergency department or are admitted to hospital. The study will also examine how long patients take antibiotics, hospital admissions, return visits to healthcare services, and patient satisfaction. Participants will be followed up by phone and through medical record review at 7 days and 30 days after their emergency visit to ensure they recover safely.

The URGE trial will study tests that are already approved and commonly used in healthcare. The goal is not to deny needed treatment, but to better match treatment to the cause of the flare-up. If successful, this approach could reduce unnecessary antibiotic use, improve patient care, and support safer, more sustainable treatment of asthma and COPD exacerbations in emergency departments.

Read the detailed description

Acute exacerbations of asthma and COPD are frequent causes of emergency department (ED) visits worldwide, with a substantial proportion of patients receiving antibiotics - often inappropriately - despite a likely viral or non-infectious etiology [1,2]. This practice contributes to antimicrobial resistance, patient harm, and unnecessary healthcare costs [3-8]. While guidelines emphasize the judicious use of antibiotics, real-time decision-making in the ED is often constrained by diagnostic uncertainty. Current approaches recommended by guidelines (GINA, GOLD, INESSS) rely heavily on symptom severity and do not systematically integrate host inflammatory or pathogen-specific data [9-12].

Leveraging evidence from previous randomized controlled trial post hoc analyses, the URGE trial is a pragmatic, randomized, open-label study designed to evaluate whether dual point-of-care testing (POCT) - combining rapid molecular microbial PCR (Polymerase Chain Reaction) testing and C-reactive protein (CRP) - can reduce antibiotic use in adults presenting to the ED with an asthma or COPD attack. This dual biomarker strategy aims to enhance diagnostic precision by integrating pathogen detection with host inflammatory responses, thereby guiding real-time, targeted decisions.

A total of 200 patients will be targeted, recruiting until at least 124 analysable patients have completed the trial. All participants will undergo microbial PCR and CRP testing after randomisation and will be managed in accordance with current clinical practice guidelines. In the intervention group, PCR and CRP results will be available to treating clinicians at the time of evaluation and used to inform management decisions. In the control group, test results will not be available to clinicians. The primary outcome is the proportion of patients prescribed antibiotics at ED discharge. Secondary outcomes include antibiotic duration, hospital admissions, revisit rates, and patient acceptability.

URGE is grounded in a growing body of evidence suggesting that either molecular microbial PCR alone or CRP can reduce antibiotic prescribing in acute respiratory illness. Molecular microbial POCT enables rapid identification of respiratory pathogens, whereas CRP reflects the host's systemic inflammatory response - particularly in response to bacterial infections- thereby facilitating early exclusion of a bacterial etiology. However, to date, no randomized trials have assessed the combined impact of these two complementary biomarkers in a real-world emergency care setting. URGE is the first study to evaluate whether integrating both markers into a unified triage strategy can synergistically improve antibiotic stewardship in patients with asthma and COPD attacks.

If successful, the URGE trial will pave the way for a biomarker-guided, proactive approach to antibiotic stewardship in acute airway disease, shifting ED management from a "treat all" paradigm to one that integrates real-time microbial identification by PCR and CRP-based inflammatory profiling. This study will inform the design of larger multicenter implementation trials and help transform care for respiratory infections in the ED.

This protocol is reported in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2025 reporting guideline [13].

03

Conditions studied

  • Asthma Acute
  • COPD Acute Exacerbation

Keywords

  • exacerbations
  • asthma
  • COPD
  • biomarkers
  • antibiotics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years at the time of signing the .
  • Presenting to the ED with a clinical diagnosis of asthma or exacerbation, defined as an acute (\<14 days) worsening of respiratory symptoms beyond baseline (e.g. increased dyspnea, cough, sputum, or wheezing) requiring urgent evaluation.
  • Established diagnosis of asthma or COPD for > 1 month*, based on:
  • For asthma: documented variability in airflow limitation (e.g., spirometric reversibility ≥12% and ≥200 mL in , or positive bronchial provocation testing), consistent with GINA 2025.
  • For COPD: post-bronchodilator FEV1/FVC \<0.70 or below the LLN with ≥10 pack-years smoking history and compatible symptoms, consistent with GOLD 2026.

    *Patients with physician-diagnosed disease, without objective testing, may undergo confirmatory testing \< 3 months after URGE trial participation to confirm eligibility.

  • Antibiotics were not ordered at the time of randomisation.
  • Able to provide signed, informed consent within the ED care window.
  • Willingness to undergo molecular microbial PCR and CRP at the point-of-care before antibiotic decision.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Clinical concern for sepsis at the time of enrolment: Altered mental status or Systolic blood pressure ≤ 100 mm Hg, unless consistent with the patient's usual baseline and without other signs of hypoperfusion.
  • Current systemic antibiotic for acute respiratory illness at time of evaluation.
  • Chronic systemic use for any indication. The first systemic corticosteroid dose given before or in the ED for the index exacerbation is permitted and does not constitute exclusion.
  • Known significant chronic respiratory disease other than asthma or , including interstitial lung disease, pulmonary hypertension, cystic fibrosis, bronchiectasis.
  • Acute use of non-invasive ventilation (NIV).
  • History of active within the past 6 months, excluding: non-melanoma skin cancer or localized cervical dysplasia / in situ cancer.
  • Significant or ongoing systemic immunosuppressive therapy (e.g., methotrexate or other immunosuppressive disease-modifying antirheumatic drugs (DMARDs), transplant recipients, chemotherapy).
  • End-stage organ disease (e.g., decompensated heart failure, end-stage renal or liver disease).
  • Severe cognitive impairment or inability to provide .
  • Pregnancy or breastfeeding.
  • Previous participation in the URGE study (participants may be enrolled only once).
  • Known (test-positive) viral infection within the past 7 days.
  • Diagnosis of pneumonia with chest X-ray made at the index visit at the clinician's discretion.
  • Concurrent acute coronary syndrome (either primary or secondary).
  • Decompensated heart failure.
  • New-onset arrhythmia.
  • Vaccination against influenza with FluMist® within 14 days prior.

Logistical or Operational Exclusions

  • Patient is unable or unwilling to undergo both POCTs.
  • Expected discharge to long-term care facility or hospice.
  • Patient self-discharges before meeting emergency care physician

Other exclusions

-Individuals are accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalised.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    POCT results disclosed

    Dual POCT results (multiplex PCR + CRP) are disclosed in real time to the treating physician, together with a predefined advisory PCR+CRP antibiotic algorithm; results are communicated to the patient. Clinicians may override the algorithm.

    Diagnostic Test: Respiratory pathogen detection via molecular PCR · Diagnostic Test: C-reactive protein (CRP) quantification · Other: Disclosure of dual POCT results with advisory PCR+CRP algorithm

  • Other
    POCT results non disclosed

    Participants undergo the same dual POCT (PCR + CRP) under identical conditions, but results are not disclosed to the treating physician or the participant during the index visit. Usual care per clinician judgment.

    Diagnostic Test: Respiratory pathogen detection via molecular PCR · Diagnostic Test: C-reactive protein (CRP) quantification

Interventions

  • Diagnostic testRespiratory pathogen detection via molecular PCR

    Rapid, point-of-care (POC) tests at the ED visit

    Also known as: BIOFIRE® SPOTFIRE® Respiratory Panel

  • Diagnostic testC-reactive protein (CRP) quantification

    Rapid, point-of-care (POC) tests at the ED visit.

    Also known as: Afinion™ CRP

  • OtherDisclosure of dual POCT results with advisory PCR+CRP algorithm

    Multiplex PCR and CRP results are disclosed in real time to the treating physician (written note in the EMR triage section), together with a predefined advisory antibiotic algorithm. Results are communicated to the patient by the treating physician. Clinicians may override the algorithm at any time.

06

What researchers measure

Primary outcomes

  1. Proportion of participants prescribed antibiotics at ED discharge

    Prescription of any antibiotic at ED discharge

    Time frame: At ED discharge or hospital admission (assessed up to 5 days)

Secondary outcomes

  1. Proportion of patients receiving only a single dose of antibiotics

    Single-dose antibiotic administration

    Time frame: During ED stay (assessed up to 5 days)

  2. Proportion of patients receiving intravenous (IV) antibiotics

    Intravenous antibiotic administration during ED stay

    Time frame: During ED stay (assessed up to 5 days)

  3. Total duration of oral antibiotic use

    Number of days of oral antibiotic therapy

    Time frame: From initiation to discontinuation (assessed up to 30 days)

  4. Total duration of IV antibiotic use

    Number of days of intravenous antibiotic therapy

    Time frame: During ED stay and/or hospitalization (assessed up to 30 days)

  5. Antibiotic prescription after ED discharge

    New antibiotic prescriptions after discharge for patients who did not receive one at discharge, and the time until that prescription was issued.

    Time frame: Day 7 and Day 30

  6. ED length of stay

    Hours from ED registration to discharge or admission order

    Time frame: From ED registration to ED discharge or admission order (assessed up to 5 days)

  7. Hospital admission rate

    Admission to hospital after ED evaluation

    Time frame: During index ED visit (assessed up to 5 days)

  8. Length of hospital stay

    Duration from hospital admission to discharge

    Time frame: From hospital admission to discharge (assessed up to 30 days)

  9. Corticosteroid prescribing at ED discharge

    Prescription of systemic corticosteroids

    Time frame: At ED discharge (assessed up to 5 days)

  10. Oseltamivir prescribing at ED discharge

    Oseltamivir prescription in PCR-confirmed influenza

    Time frame: At ED discharge (assessed up to 5 days)

  11. Time to oseltamivir initiation

    Time from randomization to first oseltamivir dose in PCR-confirmed influenza

    Time frame: From randomization to first oseltamivir dose (assessed up to 30 days)

  12. Duration of oseltamivir use

    Number of days of oseltamivir treatment in PCR-confirmed influenza

    Time frame: Through Day 30 follow-up

  13. Isolation precautions applied (mask) during ED stay

    Participants with documented initiation of respiratory isolation precautions (mask use) at any time during the ED stay.

    Time frame: During ED stay, from ED arrival to ED discharge (assessed up to 5 days)

  14. Adverse events (AEs)

    Proportion of participants with ≥1 adverse event (AE) and ≥1 serious adverse event (SAE). Severity according to CTCAE v5.0 (mild, moderate, severe).

    Time frame: Index ED visit, Day 7, and Day 30 follow-up

  15. In-hospital mortality

    Death occurring during the index ED visit or during the subsequent index hospitalization (if admitted). Reported as all-cause and asthma/COPD-related.

    Time frame: Index ED visit and index hospital admission, up to discharge (assessed up to 30 days)

  16. Unscheduled primary care consultation

    Any unplanned primary care visits after the index ED encounter. Reported as all-cause and asthma/COPD-related.

    Time frame: Day 7 and Day 30 follow-up.

  17. Unscheduled ED visits

    Return visits to any ED after the index encounter. Reported as all-cause and asthma/COPD-related

    Time frame: Day 7 and Day 30 follow-up

  18. Unscheduled hospital admission

    Any unplanned hospital admission after the index encounter. Reported as all-cause and asthma/COPD-related

    Time frame: Day 7 and Day 30 follow-up

  19. Mortality (all-cause and asthma/COPD-related)

    Death after the index ED visit, reported as all-cause and asthma/COPD-related

    Time frame: Day 7 and Day 30 follow-up

Other outcomes

  1. Time to obtain POCT PCR results

    Time from documented sample collection to PCR result availability on the POCT platform (device timestamp and/or documented availability for disclosure)

    Time frame: Index ED visit (assessed up to 5 days)

  2. Time to obtain POCT CRP results

    Time from documented sample collection to CRP result availability on the platform (device timestamp and/or documented availability for disclosure)

    Time frame: Index ED visit (assessed up to 5 days)

  3. Prevalence and distribution of respiratory viruses and bacteria detected

    Pathogen type detected by PCR

    Time frame: Index ED visit (assessed up to 5 days)

  4. Prevalence of influenza virus detected

    PCR-confirmed influenza detection

    Time frame: Index ED visit (assessed up to 5 days)

  5. Antibiotic decision-POCT concordance

    Algorithm-recommended antibiotic decision (discourage / consider / recommend) derived from the predefined CRP+PCR algorithm; and observed antibiotic prescribing status at ED discharge (yes/no), cross-classified with POCT profile (CRP strata and PCR result categories).

    Time frame: At ED discharge (assessed up to 5 days)

  6. Antibiotic prescribing based on CRP strata

    CRP level category (\<20, 20-40, \>40 mg/L)

    Time frame: At ED discharge (assessed up to 5 days)

  7. Time to antibiotic initiation

    Time from randomization to first antibiotic administration (IV or oral)

    Time frame: From randomization to first antibiotic dose (assessed up to 30 days)

  8. Atypical pathogen-targeted antibiotic (e.g. macrolide) use among participants with positive PCR for atypical bacteria.

    Initiation of an atypical pathogen-targeted antibiotic (e.g. macrolide) among participants with PCR-detected atypical bacteria

    Time frame: During ED stay (assessed up to 5 days)

  9. Patient satisfaction and acceptability of POCT strategy

    Patient-reported satisfaction

    Time frame: At ED visit (assessed up to 5 days)

  10. POCT-Laboratory PCR concordance

    Concordance between POCT PCR results and routine laboratory results when both are performed during the index ED visit

    Time frame: At ED visit (assessed up to 5 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) will be shared for all participants who consent to third-party data sharing. This includes the data underlying the published results: baseline demographic and clinical characteristics, eligibility variables, randomization arm, point-of-care test results (multiplex PCR and CRP), intervention adherence (POCT disclosure and algorithm concordance), primary and secondary outcomes (antibiotic prescribing, healthcare utilization, mortality), and adverse events. A complete data dictionary will be provided with the dataset. Data will be coded with study IDs, and all direct identifiers will be removed to prevent re-identification.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Beginning after publication of the primary outcome results and available for at least 15 years thereafter.

Access criteria: Researchers must submit a research proposal to the study investigators. Access requires approval by the investigators, a signed data-sharing agreement, and ethics approval where applicable. Data will be provided through a controlled-access repository at Université de Sherbrooke.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.

Of 599 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 23 months is close to that.

Counting every sponsor, half of 649 studies reached it within 23 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 17, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2028
CompletionEst.
Feb 28, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942298
Collaborators
BioMérieux
Responsible party
Simon Couillard (Professor, Université de Sherbrooke) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion